Blood modifications associated with end stage renal disease duration, progression and cardiovascular mortality: A 3-year follow-up pilot study

Journal of Proteomics

Volumn 101, Issue , 2014, Pages 88-101

  Antonelou, Marianna H ^a   Georgatzakou, Hara T ^a   Tzounakas, Vasillis L ^a   Velentzas, Athanassios D ^a   Kokkalis, Apostolos C ^b   Kriebardis, Anastasios G ^c   Papassideri, Issidora S ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Chronic Hemodialysis Centre Ionion   (Greece)

^c UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

Cardiovascular mortality; End stage renal disease; Membrane proteins; Oxidative stress; Protein carbonylation; Red blood cell

Indexed keywords

ALKALINE PHOSPHATASE; ERYTHROPOIETIN; GLUCOSE TRANSPORTER 1; STOMATIN; UREMIC TOXIN; BIOLOGICAL MARKER; PLASMA PROTEIN;

AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; END STAGE RENAL DISEASE; ERYTHROCYTE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; IN VIVO STUDY; INTRACELLULAR MEMBRANE; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; ADULT; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; METABOLISM; MIDDLE AGED; MORTALITY; PROTEOMICS; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD PROTEINS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PILOT PROJECTS; PROTEOMICS; TIME FACTORS;

EID: 84896886239     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.02.009     Document Type: Article

References (74)

1. Lindner A., Charra B., Sherrard D.J., Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974, 290:697-701.
2. Slinin Y., Foley R.N., Collins A.J. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005, 16:1788-1793.
3. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999, 55:648-658.
4. Zoccali C. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors?. Nephrol Dial Transplant 2000, 15:454-457.
5. Miyazaki H., Matsuoka H., Itabe H., Usui M., Ueda S., Okuda S., et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 2000, 101:1002-1006.
6. Locatelli F., Canaud B., Eckardt K.U., Stenvinkel P., Wanner C., Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003, 18:1272-1280.
7. Eckardt K.U. Pathophysiology of renal anemia. Clin Nephrol 2000, 53:S2-S8.
8. Antonelou M.H., Kriebardis A.G., Velentzas A.D., Kokkalis A.C., Georgakopoulou S.C., Papassideri I.S. Oxidative stress-associated shape transformation and membrane proteome remodeling in erythrocytes of end stage renal disease patients on hemodialysis. J Proteomics 2011, 74:2441-2452.
9. Bakaev V.V., Efremov A.V., Tityaev I.I. Low levels of dehydroascorbic acid in uraemic serum and the partial correction of dehydroascorbic acid deficiency by haemodialysis. Nephrol Dial Transplant 1999, 14:1472-1474.
10. Pavone B., Sirolli V., Bucci S., Libardi F., Felaco P., Amoroso L., et al. Adsorption and carbonylation of plasma proteins by dialyser membrane material: in vitro and in vivo proteomics investigations. Blood Transfus 2010, 8(Suppl. 3):s113-s119.
11. Kalogerakis G., Baker A.M., Christov S., Rowley K.G., Dwyer K., Winterbourn C., et al. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease. Clin Sci (Lond) 2005, 108:497-506.
12. Roberts M.A., Hare D.L., Ratnaike S., Ierino F.L. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 2006, 48:341-360.
13. Stenvinkel P., Carrero J.J., Axelsson J., Lindholm B., Heimburger O., Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 2008, 3:505-521.
14. Chaykovska L., Tsuprykov O., Hocher B. Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy. Clin Lab 2011, 57:455-467.
15. Ortiz A., Massy Z.A., Fliser D., Lindholm B., Wiecek A., Martinez-Castelao A., et al. Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol 2012, 8:141-150.
16. Benzie I.F., Strain J.J. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol 1999, 299:15-27.
17. Duplancic D., Kukoc-Modun L., Modun D., Radic N. Simple and rapid method for the determination of uric acid-independent antioxidant capacity. Molecules 2011, 16:7058-7068.
18. Antonelou M.H., Tzounakas V.L., Velentzas A.D., Stamoulis K.E., Kriebardis A.G., Papassideri I.S. Effects of pre-storage leukoreduction on stored red blood cells signaling: a time-course evaluation from shape to proteome. J Proteomics 2012, 76 Spec No.:220-238.
19. Beutler E., West C., Blume K.G. The removal of leukocytes and platelets from whole blood. J Lab Clin Med 1976, 88:328-333.
20. Antonelou M.H., Kriebardis A.G., Stamoulis K.E., Economou-Petersen E., Margaritis L.H., Papassideri I.S. Red blood cell aging markers during storage in citrate-phosphate-dextrose-saline-adenine-glucose-mannitol. Transfusion 2010, 50:376-389.
21. Berezina T.L., Zaets S.B., Morgan C., Spillert C.R., Kamiyama M., Spolarics Z., et al. Influence of storage on red blood cell rheological properties. J Surg Res 2002, 102:6-12.
22. D'Alessandro A., D'Amici G.M., Vaglio S., Zolla L. Time-course investigation of SAGM-stored leukocyte-filtered red bood cell concentrates: from metabolism to proteomics. Haematologica 2012, 97:107-115.
23. Jackson P., Loughrey C.M., Lightbody J.H., McNamee P.T., Young I.S. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 1995, 41:1135-1138.
24. Benzie I.F., Strain J.J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996, 239:70-76.
25. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003, 42:1050-1065.
26. Iseki K., Tozawa M., Takishita S. Effect of the duration of dialysis on survival in a cohort of chronic haemodialysis patients. Nephrol Dial Transplant 2003, 18:782-787.
27. Lomashvili K.A., Garg P., Narisawa S., Millan J.L., O'Neill W.C. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008, 73:1024-1030.
28. Kerner A., Avizohar O., Sella R., Bartha P., Zinder O., Markiewicz W., et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005, 25:193-197.
29. Blayney M.J., Pisoni R.L., Bragg-Gresham J.L., Bommer J., Piera L., Saito A., et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008, 74:655-663.
30. Beddhu S., Baird B., Ma X., Cheung A.K., Greene T. Serum alkaline phosphatase and mortality in hemodialysis patients. Clin Nephrol 2010, 74:91-96.
31. Ofsthun N., Labrecque J., Lacson E., Keen M., Lazarus J.M. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003, 63:1908-1914.
32. Avram M.M., Blaustein D., Fein P.A., Goel N., Chattopadhyay J., Mittman N. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int Suppl 2003, S6-S11.
33. Eschbach J.W., Adamson J.W. Guidelines for recombinant human erythropoietin therapy. Am J Kidney Dis 1989, 14:2-8.
34. Phrommintikul A., Haas S.J., Elsik M., Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007, 369:381-388.
35. Vaziri N.D. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999, 33:821-828.
36. Reinhart W.H., Cagienard F., Schulzki T., Venzin R.M. The passage of a hemodialysis filter affects hemorheology, red cell shape, and platelet aggregation. Clin Hemorheol Microcirc 2013.
37. Amabile N., Guerin A.P., Leroyer A., Mallat Z., Nguyen C., Boddaert J., et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005, 16:3381-3388.
38. Mallat Z., Benamer H., Hugel B., Benessiano J., Steg P.G., Freyssinet J.M., et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000, 101:841-843.
39. Daniel L., Fakhouri F., Joly D., Mouthon L., Nusbaum P., Grunfeld J.P., et al. Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int 2006, 69:1416-1423.
40. Wagner G.M., Chiu D.T., Qju J.H., Heath R.H., Lubin B.H. Spectrin oxidation correlates with membrane vesiculation in stored RBCs. Blood 1987, 69:1777-1781.
41. Glaser T., Schwarz-Benmeir N., Barnoy S., Barak S., Eshhar Z., Kosower N.S. Calpain (Ca(2+)-dependent thiol protease) in erythrocytes of young and old individuals. Proc Natl Acad Sci U S A 1994, 91:7879-7883.
42. Schwarz-Ben Meir N., Glaser T., Kosower N.S. Band 3 protein degradation by calpain is enhanced in erythrocytes of old people. Biochem J 1991, 275(Pt 1):47-52.
43. Saradhadevi V., Sakthivel R., Vedamoorthy S., Selvam R., Parinandi N. Alterations in band 3 protein and anion exchange in red blood cells of renal failure patients. Mol Cell Biochem 2005, 273:11-24.
44. Mansouri A., Perry C.A. Hemoglobin autoxidation at physiological concentrations. Hemoglobin 1987, 11:353-371.
45. Margetis P., Antonelou M., Karababa F., Loutradi A., Margaritis L., Papassideri I. Physiologically important secondary modifications of red cell membrane in hereditary spherocytosis-evidence for in vivo oxidation and lipid rafts protein variations. Blood Cells Mol Dis 2007, 38:210-220.
46. Miyata T., Kurokawa K., van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int Suppl 2000, 76:S120-S125.
47. Rocha S., Costa E., Coimbra S., Nascimento H., Catarino C., Rocha-Pereira P., et al. Linkage of cytosolic peroxiredoxin 2 to erythrocyte membrane imposed by hydrogen peroxide-induced oxidative stress. Blood Cells Mol Dis 2009, 43:68-73.
48. Rinalducci S., D'Amici G.M., Blasi B., Vaglio S., Grazzini G., Zolla L. Peroxiredoxin-2 as a candidate biomarker to test oxidative stress levels of stored red blood cells under blood bank conditions. Transfusion 2011, 51:1439-1449.
49. Stuhlmeier K.M., Kao J.J., Wallbrandt P., Lindberg M., Hammarstrom B., Broell H., et al. Antioxidant protein 2 prevents methemoglobin formation in erythrocyte hemolysates. Eur J Biochem 2003, 270:334-341.
50. Low F.M., Hampton M.B., Winterbourn C.C. Peroxiredoxin 2 and peroxide metabolism in the erythrocyte. Antioxid Redox Signal 2008, 10:1621-1630.
51. Moore R.B., Shriver S.K. Protein 7.2b of human erythrocyte membranes binds to calpromotin. Biochem Biophys Res Commun 1997, 232:294-297.
52. Rocha S., Vitorino R.M., Lemos-Amado F.M., Castro E.B., Rocha-Pereira P., Barbot J., et al. Presence of cytosolic peroxiredoxin 2 in the erythrocyte membrane of patients with hereditary spherocytosis. Blood Cells Mol Dis 2008, 41:5-9.
53. Brzeszczynska J., Luciak M., Gwozdzinski K. Alterations of erythrocyte structure and cellular susceptibility in patients with chronic renal failure: effect of haemodialysis and oxidative stress. Free Radic Res 2008, 42:40-48.
54. Harrison M.L., Rathinavelu P., Arese P., Geahlen R.L., Low P.S. Role of band 3 tyrosine phosphorylation in the regulation of erythrocyte glycolysis. J Biol Chem 1991, 266:4106-4111.
55. Walsh S.B., Stewart G.W. Anion exchanger 1: protean function and associations. Int J Biochem Cell Biol 2010, 42:1919-1922.
56. Khan A.A., Hanada T., Mohseni M., Jeong J.J., Zeng L., Gaetani M., et al. Dematin and adducin provide a novel link between the spectrin cytoskeleton and human erythrocyte membrane by directly interacting with glucose transporter-1. J Biol Chem 2008, 283:14600-14609.
57. Trougakos I.P., Poulakou M., Stathatos M., Chalikia A., Melidonis A., Gonos E.S. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol 2002, 37:1175-1187.
58. Antonelou M.H., Kriebardis A.G., Stamoulis K.E., Trougakos I.P., Papassideri I.S. Apolipoprotein J/clusterin is a novel structural component of human erythrocytes and a biomarker of cellular stress and senescence. PLoS One 2011, 6:e26032.
59. Antonelou M.H., Kriebardis A.G., Stamoulis K.E., Trougakos I.P., Papassideri I.S. Apolipoprotein J/clusterin in human erythrocytes is involved in the molecular process of defected material disposal during vesiculation. PLoS One 2011, 6:e26033.
60. Lin Y.P., Yang C.Y., Liao C.C., Yu W.C., Chi C.W., Lin C.H. Plasma protein characteristics of long-term hemodialysis survivors. PLoS One 2012, 7:e40232.
61. Ruttmann E., Brant L.J., Concin H., Diem G., Rapp K., Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112:2130-2137.
62. Bosman G.J., Lasonder E., Groenen-Dopp Y.A., Willekens F.L., Werre J.M. The proteome of erythrocyte-derived microparticles from plasma: new clues for erythrocyte aging and vesiculation. J Proteomics 2012, 76 Spec No.:203-210.
63. Hwang D.Y., Ismail-Beigi F. Stimulation of GLUT-1 glucose transporter expression in response to hyperosmolarity. Am J Physiol Cell Physiol 2001, 281:C1365-C1372.
64. Boado R.J., Pardridge W.M. Glucose deprivation and hypoxia increase the expression of the GLUT1 glucose transporter via a specific mRNA cis-acting regulatory element. J Neurochem 2002, 80:552-554.
65. Alvarez-Llamas G., Zubiri I., Maroto A.S., de la Cuesta F., Posada-Ayala M., Martin-Lorenzo M., et al. A role for the membrane proteome in human chronic kidney disease erythrocytes. Transl Res 2012, 160:374-383.
66. May J.M. Ascorbate function and metabolism in the human erythrocyte. Front Biosci 1998, 3:d1-d10.
67. Rumsey S.C., Kwon O., Xu G.W., Burant C.F., Simpson I., Levine M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol Chem 1997, 272:18982-18989.
68. Zhang J.Z., Hayashi H., Ebina Y., Prohaska R., Ismail-Beigi F. Association of stomatin (band 7.2b) with Glut1 glucose transporter. Arch Biochem Biophys 1999, 372:173-178.
69. Montel-Hagen A., Kinet S., Manel N., Mongellaz C., Prohaska R., Battini J.L., et al. Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C. Cell 2008, 132:1039-1048.
70. Zhang J.Z., Abbud W., Prohaska R., Ismail-Beigi F. Overexpression of stomatin depresses GLUT-1 glucose transporter activity. Am J Physiol Cell Physiol 2001, 280:C1277-C1283.
71. Rungaldier S., Oberwagner W., Salzer U., Csaszar E., Prohaska R. Stomatin interacts with GLUT1/SLC2A1, band 3/SLC4A1, and aquaporin-1 in human erythrocyte membrane domains. Biochim Biophys Acta 1828, 2013:956-966.
72. Zarychanski R., Schulz V.P., Houston B.L., Maksimova Y., Houston D.S., Smith B., et al. Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis. Blood 2012, 120:1908-1915.
73. Albuisson J., Murthy S.E., Bandell M., Coste B., Louis-Dit-Picard H., Mathur J., et al. Dehydrated hereditary stomatocytosis linked to gain-of-function mutations in mechanically activated PIEZO1 ion channels. Nat Commun 2013, 4:1884.
74. Faucherre A., Kissa K., Nargeot J., Mangoni M., Jopling C. Piezo1 plays a role in erythrocyte volume homeostasis. Haematologica 2013.